Market Insider

Early movers FIATY, AAPL, GOOG, BAC, CPB, S & more

Traders work on the floor of the New York Stock Exchange.
Getty Images

Check out which companies are making headlines before the bell:

Fiat —The automaker finally reached a long-sought agreement to buy the shares of Chrysler it doesn't already own for $3.65 billion. The stock has been owned by a United Auto Workers union health care trust.

Apple–The iPhone maker was downgraded to "market perform" from "outperform" at Wells Fargo, which points to valuation as well as possible profit margin pressure at whatever time Apple introduces another new version of the iPhone.

Bank of America–Citi upgraded B of A to "buy" from "neutral", saying the bank is no longer impacted by legacy issues.

Fiat buys remaining stake in Chrysler
VIDEO2:1202:12
Fiat buys remaining stake in Chrysler

Google–The search giant is shutting down recently acquired Bump, so that the Bump team can work on other Google projects. The unit is the developer of software that allows smartphones to transfer information by tapping them together.

Newmont Mining, Goldcorp–These and other gold producers could get a bump today, as gold rallies following the metal's biggest yearly drop in 32 years.

Campbell Soup–Campbell has issued a recall for about 300 cases of Prego Traditional Italian sauce, saying there is a risk of spoilage.

Diageo, Barclays, and Nokia–The three are among the U.S.-traded stocks included in Bank of America Merrill Lynch's top EMEA (Europe, Middle East, and Africa) stock ideas for the first quarter.

Xilinx–The stock has been upgraded to "buy" from "neutral" at Goldman Sachs, while rival specialty chip maker Altera has been cut to "neutral" from "buy".

Retailers–Jefferies upgraded retailers American Eagle, , , and to "buy" from "hold", saying they've done well in a challenging environment, while cutting and to "hold" from "buy", citing what Jefferies sees as a long recovery period following difficult times.

–The drug maker entered an agreement with (CVS) which will make its diet drug Qsymia available for co-payments of $15 to $75 in cases where patients have obesity coverage.

–The mobile carrier's stock was cut to "market perform" from "outperform" at Cowen & Co., which still has a positive long term outlook but said the stock is currently ahead of where it should be.

–Goldman Sachs removed the stock from its "conviction buy" list, although a "buy" rating remains. Goldman cites a more balanced risk/reward ratio at current levels, but also raised the 12-month price target to $37 based on T-Mobile's possible value as a takeover target.

—By CNBC's Peter Schacknow

Questions? Comments? Email us at marketinsider@cnbc.com